Ali Farzanegan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ali Farzanegan has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
Halala Khalandi
Department of Parasitology and Mycology, Iran University of Medical Science, Tehran, Iran
2 shared publications- Mehraban Falahati
Department of Parasitology and Mycology, Iran University of Medical Science, Tehran, Iran
2 shared publications Ali Akbar Delbandi
Immunology Research Center, Immunology and Infectious Disease Institute, Iran University of Medical Sciences, Tehran, Iran
1 shared publicationAzam Fattahi
Research Center of Pediatric Infectious Diseases, Institute of Immunology and Infectious Diseases, Iran University of Medical Sciences, Tehran, Iran
1 shared publicationE. Gholibegloo
Department of Chemistry, Faculty of Sciences, University of Zanjan, Zanjan, Iran
1 shared publicationFariba Heydarikohan
Department of Medical Parasitology and Mycology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
1 shared publication
Latest Publications
- Open Access
- 30 December 2021
- Published by CMV Verlag in Journal of Current Biomedical Reports
- Vol. 2 (4) , 150-158
Fungi associated oral cavity hygiene and denture stomatitis: A review on diagnostic and treatment
Fungi associated oral cavity hygiene and denture stomatitis: A review on diagnostic and treatment
- 30 December 2021
- Published by CMV Verlag in Journal of Current Biomedical Reports
- Vol. 2 (4) , 150-158
Open AccessFungi associated oral cavity hygiene and denture stomatitis: A review on diagnostic and treatment
Fungi associated oral cavity hygiene and denture stomatitis: A review on diagnostic and treatment
- Open Access
- 11 April 2021
- Published by CMV Verlag in Journal of Current Biomedical Reports
- Vol. 2 (2) , 74-78
Decrease of microbial contamination by application of routinely glycerol and phenol solution on human cadavers
Decrease of microbial contamination by application of routinely glycerol and phenol solution on human cadavers
- 11 April 2021
- Published by CMV Verlag in Journal of Current Biomedical Reports
- Vol. 2 (2) , 74-78
Open AccessDecrease of microbial contamination by application of routinely glycerol and phenol solution on human cadavers
Decrease of microbial contamination by application of routinely glycerol and phenol solution on human cadavers
- 21 May 2020
- Published by SAGE Publications in ASSAY and Drug Development Technologies
- Vol. 18 (4) , 195-201
Antifungal Activity of Capric Acid, Nystatin, and Fluconazole and Their In Vitro Interactions Against Candida Isolates from Neonatal Oral Thrush
Due to the increasing resistance of various Candida species to azole drugs, particularly fluconazole, it would be of significant importance to look for alternative therapies. The aim of this study was to investigate the antifungal activity of capric acid and its in vitro interactions with nystatin and fluconazole against Candida isolates. A total of 40 Candida isolates ( C. albicans , 36; C. kefyr , 2; C. tropicalis , 1; C. glabrata , 1) collected from the oral cavity of neonates with oropharyngeal candidiasis and a reference strain of C. albicans (ATCC 10231) were used in this study. Antifungal activity of capric acid and two comparator antifungal drugs, namely fluconazole and nystatin, was tested according to CLSI M27-A3/M60 method. The in vitro interaction between capric acid with fluconazole and nystatin was determined following a checkerboard method and results were interpreted using fractional inhibitory concentration index. Nystatin had the lowest minimum inhibitory concentrations (range, 0.125–8 μg/mL; geometric mean [GM], 0.6229 μg/mL) followed by fluconazole (range, 0.5–16 μg/mL; GM, 1.9011 μg/mL) and capric acid (range, 128–2,048 μg/mL; GM, 835.9756 μg/mL). When tested in combination, capric acid with fluconazole demonstrated synergistic, indifferent, and antagonistic interactions in 3 (7.317%), 24 (58.536%), and 14 (34.146%) cases, respectively. For combination of capric acid with nystatin, synergistic, indifferent, and antagonistic interactions were observed in 1 (2.439%), 19 (46.341%), and 21 (51.219%) cases, respectively. All cases of synergistic interactions were against resistant or susceptible dose-dependent isolates. Fluconazole, nystatin, and capric acid seem to be more effective when they are used alone compared with their combination. However, their combination might be effective on resistant isolates.
- 21 May 2020
- Published by SAGE Publications in ASSAY and Drug Development Technologies
- Vol. 18 (4) , 195-201
Antifungal Activity of Capric Acid, Nystatin, and Fluconazole and Their In Vitro Interactions Against Candida Isolates from Neonatal Oral Thrush
Due to the increasing resistance of various Candida species to azole drugs, particularly fluconazole, it would be of significant importance to look for alternative therapies. The aim of this study was to investigate the antifungal activity of capric acid and its in vitro interactions with nystatin and fluconazole against Candida isolates. A total of 40 Candida isolates ( C. albicans , 36; C. kefyr , 2; C. tropicalis , 1; C. glabrata , 1) collected from the oral cavity of neonates with oropharyngeal candidiasis and a reference strain of C. albicans (ATCC 10231) were used in this study. Antifungal activity of capric acid and two comparator antifungal drugs, namely fluconazole and nystatin, was tested according to CLSI M27-A3/M60 method. The in vitro interaction between capric acid with fluconazole and nystatin was determined following a checkerboard method and results were interpreted using fractional inhibitory concentration index. Nystatin had the lowest minimum inhibitory concentrations (range, 0.125–8 μg/mL; geometric mean [GM], 0.6229 μg/mL) followed by fluconazole (range, 0.5–16 μg/mL; GM, 1.9011 μg/mL) and capric acid (range, 128–2,048 μg/mL; GM, 835.9756 μg/mL). When tested in combination, capric acid with fluconazole demonstrated synergistic, indifferent, and antagonistic interactions in 3 (7.317%), 24 (58.536%), and 14 (34.146%) cases, respectively. For combination of capric acid with nystatin, synergistic, indifferent, and antagonistic interactions were observed in 1 (2.439%), 19 (46.341%), and 21 (51.219%) cases, respectively. All cases of synergistic interactions were against resistant or susceptible dose-dependent isolates. Fluconazole, nystatin, and capric acid seem to be more effective when they are used alone compared with their combination. However, their combination might be effective on resistant isolates.
- 1 December 2018
- Published by Elsevier in Journal of Medical Mycology
- Vol. 28 (4) , 628-636
Synthesis, characterization and antifungal activity of a novel formulated nanocomposite containing Indolicidin and Graphene oxide against disseminated candidiasis
- 1 December 2018
- Published by Elsevier in Journal of Medical Mycology
- Vol. 28 (4) , 628-636
Synthesis, characterization and antifungal activity of a novel formulated nanocomposite containing Indolicidin and Graphene oxide against disseminated candidiasis
Is mannose‐binding lectin serum concentration a reliable predictor for recurrent vulvovaginal candidiasis?
Summary: Recurrent vulvovaginal candidiasis (RVVC) is a common opportunistic, mucosal fungal infection, predominantly caused by the fungus Candida albicans. Mannose‐binding lectin (MBL) is an acute‐phase protein that plays a key role in the innate immunity defence against infectious disease. This study was conducted to evaluate the relationship between the MBL serum level and the relative expression of MBL mRNA in RVVC using real‐time PCR for the first time. The case‐control study included 40 female participants suffering from RVVC and 40 healthy individuals. The MBL serum level was measured using a commercial ELISA kit. The relative mRNA expression of the MBL gene was quantified using real‐time PCR. Data analysis was carried out by spss software. The MBL concentration was significantly higher in the participants suffering from RVVC compared to the control group (0.330 ng/mL vs 0.253 ng/mL). The prognostic value (P < .001) for RVVC diagnosis has been calculated. Quantitative RT‐PCR results from 35 samples showed a low to significant values for mRNA levels corresponding to MBL gene expression (1‐352 folds) (P < .001). The results of this study suggest that MBL plays a main role in the innate immunity and it is also affected by environmental factors and other genetic variations. Therefore, the MBL gene expression profile does not reflect precise phenotypic levels in the serum.
Is mannose‐binding lectin serum concentration a reliable predictor for recurrent vulvovaginal candidiasis?
Summary: Recurrent vulvovaginal candidiasis (RVVC) is a common opportunistic, mucosal fungal infection, predominantly caused by the fungus Candida albicans. Mannose‐binding lectin (MBL) is an acute‐phase protein that plays a key role in the innate immunity defence against infectious disease. This study was conducted to evaluate the relationship between the MBL serum level and the relative expression of MBL mRNA in RVVC using real‐time PCR for the first time. The case‐control study included 40 female participants suffering from RVVC and 40 healthy individuals. The MBL serum level was measured using a commercial ELISA kit. The relative mRNA expression of the MBL gene was quantified using real‐time PCR. Data analysis was carried out by spss software. The MBL concentration was significantly higher in the participants suffering from RVVC compared to the control group (0.330 ng/mL vs 0.253 ng/mL). The prognostic value (P < .001) for RVVC diagnosis has been calculated. Quantitative RT‐PCR results from 35 samples showed a low to significant values for mRNA levels corresponding to MBL gene expression (1‐352 folds) (P < .001). The results of this study suggest that MBL plays a main role in the innate immunity and it is also affected by environmental factors and other genetic variations. Therefore, the MBL gene expression profile does not reflect precise phenotypic levels in the serum.